A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation

References

• Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15:Epub ahead of print
   Web of Science ®Google Scholar
• Lip GY, Fauchier L, Freedman SB, et al. Atrial fibrillation. Nat Rev Dis Primers. 2016;2:16016.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.
   PubMed Web of Science ®Google Scholar
• Fitch K, Broulette J, Kwong WJ. The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis. Am Health Drug Benefits. 2014;7:200–209.
   PubMedGoogle Scholar
• Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin. 2016;32:573–582.
   PubMed Web of Science ®Google Scholar
• Raschi E, Bianchin M, Ageno W, et al. Risk-benefit profile of direct-acting oral anticoagulants in established therapeutic indications: an overview of systematic reviews and observational studies. Drug Saf. 2016;39:1175–1187.
   PubMed Web of Science ®Google Scholar
• Pokorney SD, Simon DN, Thomas L, et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015;170:141–148, 148 e141.
   PubMed Web of Science ®Google Scholar
• Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther. 2008;6:57–70.
   PubMedGoogle Scholar
• Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. Int J Clin Pract. 2016;70:752–763.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Kuroda J, Ago T, et al. Causes of ischemic stroke in patients with non-valvular atrial fibrillation. Cerebrovasc Dis. 2016;42:196–204.
   PubMedGoogle Scholar
• US Food & Drug Administration. Dabigatran prescribing information. 2010 [last accessed October 26, 2017]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ba74e3c d-b06f-4145-b284-5fd6b84ff3c9&type=display.
   Google Scholar
• US Food & Drug Administration. Rivaroxaban prescribing information. 2011 [last accessed October 26, 2017]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=10db92 f9-2300-4a80-836b-673e1ae91610&type=display.
   Google Scholar
• US Food & Drug Administration. Apixaban prescribing information. 2012 [last accessed October 26, 2017]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e9481622-7 cc6-418a-acb6-c5450daae9b0&type=display.
   Google Scholar
• US Food & Drug Administration. Edoxaban prescribing information. 2015 [last accessed October 26, 2017]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66&type=display.
   Google Scholar
• European Medicines Agency. Dabigatran summary of product characteristics. 2008 [last accessed November 15, 2017] . Available from: http://www.medicines.org.uk/emc/medicine/20760.
   Google Scholar
• European Medicines Agency. Rivaroxaban summary of product characteristics. 2008 [last accessed November 15, 2017]. Available from: http://www.medicines.org.uk/emc/medicine/29371.
   Google Scholar
• European Medicines Agency. Apixaban summary of product characteristics. 2011 [last accessed November 15, 2017]. Available from: http://www.medicines.org.uk/emc/medicine/24988.
   Google Scholar
• European Medicines Agency. Edoxaban summary of product characteristics. 2015 [last accessed November 15, 2017]. Available from: http://www.medicines.org.uk/emc/medicine/30513.
   Google Scholar
• Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52:69–82.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Lip GY, Al-Khatib SM, Cosio FG, et al. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc. 2014;3:pii: e001179.
   PubMedGoogle Scholar
• Ganann R, Ciliska D, Thomas H. Expediting systematic reviews: methods and implications of rapid reviews. Implement Sci. 2010;5:56.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Kelly SE, Moher D, Clifford TJ. Quality of conduct and reporting in rapid reviews: an exploration of compliance with PRISMA and AMSTAR guidelines. Syst Rev. 2016;5:79.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Xie L. Comparison of short-term bleeding-related health care utilization and costs among treatment-naive nonvalvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. Chest. 2015;148:65A.
   Web of Science ®Google Scholar
• Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;68:1389–1401.
   PubMed Web of Science ®Google Scholar
• Charlton B, Adeboyeje G, Barron J. Length of hospital stay and all-cause mortality among adults with atrial fibrillation hospitalized for bleeding during treatment with warfarin, dabigatran, or rivaroxaban. Circulation. 2015;132:A11583.
   Web of Science ®Google Scholar
• Fu A, Jain A, Sander S. Healthcare utilization and medication persistence of dabigatran and warfarin use for stroke-prevention among newly-diagnosed patients with non-valvular atrial fibrillation. American College of Preventive Medicine (ACPM) Annual Meeting; February 19–22, 2014; New Orleans, LA.
   Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662–1671.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–164.
   PubMed Web of Science ®Google Scholar
• Lau W, Li XL, Wong I. Hospitalization and length of stay among patients with non-valvular atrial fibrillation taking dabigatran or warfarin: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2016;25:499.
   Google Scholar
• Maura G, Blotiere PO, Bouillon K, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015;132:1252–1260.
   PubMed Web of Science ®Google Scholar
• Michels S, Sheer R, Ghate R. All-cause and driver-specific healthcare resource utilization in newly diagnosed non-valvular atrial fibrillation patients newly initiating dabigatran or warfarin. Academy of Managed Care Pharmacy Annual Meeting; April 1-4, 2015; Tampa, FL; 2015. p. S33.
   Google Scholar
• Pan X, Kamble S, Burns L. What do real world data say about safety and resource use of oral antagonists? Early analysis of newly anticoagulated non-valvular artrial fibrillation patients using either apixaban, dabigatran, rivaroxaban or warfarin. 65th Annual Scientific Session and Expo of the American College of Cardiology and i2 Summit; April 2–4, 2016; Chicago, IL.
   Google Scholar
• Singer AJ, Quinn A, Dasgupta N, et al. Management and outcomes of bleeding events in patients in the emergency department taking warfarin or a non-vitamin K antagonist oral anticoagulant. J Emerg Med. 2017;52:1–7 e1.
   PubMed Web of Science ®Google Scholar
• Smythe MA, Forman MJ, Bertran EA, et al. Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients. J Thromb Thrombolysis. 2015;40:280–287.
   PubMed Web of Science ®Google Scholar
• Song X, Gandhi P, Gilligan A. Comparison of stroke- and bleed-specific healthcare resource utilization and costs among patients with non-valvular atrial fibrillation, newly treated with dabigatran or warfarin. Blood. 2016;128:532.
   Web of Science ®Google Scholar
• Tepper P, Mardekian J, Masseria C. Real-world comparison of inpatient bleeding risk, bleeding-related hospitalization rates and costs among non-valvular atrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or switchers from warfarin. 65th Annual Scientific Session of the American College of Cardiology and i2 Summit; April 2–4, 2016; Chicago, IL. J Am Coll Cardiol; 2016. p. S662.
   Google Scholar
• Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol. 2015;38:63–68.
   PubMed Web of Science ®Google Scholar
• Peacock W, Patel M, Tamayo S. Major bleeding in a post-marketing assessment of 39,052 non-valvular atrial fibrillation patients on rivaroxaban. ESC Congress; August 29–September 2, 2015; London, United Kingdom. Eur Heart J; 2015. p. 96.
   Google Scholar
• Tamayo S, Patel M, Yuan Z. Major bleeding in rivaroxaban users with non-valvular atrial fibrillation in an older adult population. American Geriatrics Society 2015 Annual Scientific Meeting; 2015 May 15–17; National Harbor, MD. J Am Geriatr Soc; 2015. p. S221.
   Web of Science ®Google Scholar
• Deitelzweig S, Bruno A, Tate N. Early assessment of bleeding-related hospital readmissions among nonvalvular atrial fibrillation patients treated with the new oral anticoagulants using an electronic medical record database in the US. ESC Congress; August 29–September 2, 2015; London, United Kingdom. Eur Heart J; 2015. p. 1083.
   PubMed Web of Science ®Google Scholar
• Milling TJ, Fromm C, Ganetsky M, et al. Management of major bleeding events in patients treated with dabigatran for nonvalvular atrial fibrillation: a retrospective, multicenter review. Ann Emerg Med. 2017;69:531–540.
   PubMed Web of Science ®Google Scholar
• Rodriguez P, Paredes-Galan P, Vilches-Moraga A. Safety of dabigatran etexilate in frail older old patients with non-valvular atrial fibrillation. ESC Congress; August 31–September 4, 2013; Amsterdam, Netherlands. Eur Heart J; 2013. p. 96.
   PubMed Web of Science ®Google Scholar
• Tamayo S, Patel M, Yuan Z. Post-marketing pharmacovigilance study for the active detection and evaluation of major bleeding in rivaroxaban users with non-valvular atrial fibrillation. 64th Annual Scientific Session of the American College of Cardiology and i2 Summit; March 14–16, 2015; San Diego, CA. J Am Coll Cardiol; 2015. p. A281.
   PubMedGoogle Scholar
• Amin A, Keshishian A, Xie L. Comparison of major-bleeding risk and health care costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. American Heart Association 2015 Scientific Session; November 7–11, 2015; Orlando, FL. Circulation; 2015. p. A19672.
   Google Scholar
• Amin A, Keshishian A, Xie L. Early comparison of major bleeding, stroke and associated medical costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. Blood. 2016;126:745.
   Web of Science ®Google Scholar
• Deitelzweig S, Bruno A, Tate N. Comparison of major bleeding risk and associated costs among newly anticoagulated non-valvular atrial fibrillation patients. American Heart Association 2015 Scientific Sessions and Resuscitation Science Symposium; November 7–11, 2015; Orlando, FL. Circulation; 2015. p. A16398.
   Google Scholar
• Deitelzweig S, Gupta K, Ogbonnaya A. Compare major bleeding risk and associated costs among NVAF patients with CHA2DS2-vasc score >3 newly anticoagulated with apixaban versus warfarin. 65th Annual Scientific Session of the American College of Cardiology; April 2–4, 2016; Chicago, IL. Journal of the American College of Cardiology; 2016. p. 876.
   PubMed Web of Science ®Google Scholar
• Francis K, Yu C, Alvrtsyan H, et al. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;31:2189–2195.
   PubMed Web of Science ®Google Scholar
• Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis. PLoS One. 2015;10:e0137444.
   PubMed Web of Science ®Google Scholar
• Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015;101:1204–1211.
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Dherange P, et al. A comparison of oral anticoagulant use for atrial fibrillation in the pre- and post-DOAC eras. Drugs Aging. 2016;33:427–436.
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645 e634.
   PubMed Web of Science ®Google Scholar
• Huhtakangas J, Tetri S, Juvela S, et al. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke. 2011;42:2431–2435.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414–1419.
   PubMed Web of Science ®Google Scholar
• Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442–3453.
   PubMed Web of Science ®Google Scholar
• AbuDagga A, Stephenson JJ, Fu AC, et al. Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res. 2014;14:310.
   PubMed Web of Science ®Google Scholar
• Baik SH, Hernandez I, Zhang Y. Evaluating the initiation of novel oral anticoagulants in Medicare beneficiaries. J Manag Care Spec Pharm. 2016;22:281–292.
   PubMedGoogle Scholar
• Schoof N, Schnee J, Schneider G, et al. Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin. 2014;30:795–804.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. Idarucizumab prescribing information. 2015 [last accessed October 26, 2017] . Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c 7400f8a-dcf4-a6df-6d07-983081b1bf34&type=display.
   Google Scholar
• European Medicines Agency. Idarucizumab Summary of Product Characteristics. 2015 [last accessed November 15, 2017]. Available from: http://www.medicines.org.uk/emc/medicine/31243.
   Google Scholar
• Pollack CV, Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
   PubMed Web of Science ®Google Scholar
• Beasley BN, Unger EF, Temple R. Anticoagulant options–why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364:1788–1790.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Holmes DN, Piccini JP, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013;2:e000535.
   PubMed Web of Science ®Google Scholar